ATE266021T1 - Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren - Google Patents

Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren

Info

Publication number
ATE266021T1
ATE266021T1 AT01907980T AT01907980T ATE266021T1 AT E266021 T1 ATE266021 T1 AT E266021T1 AT 01907980 T AT01907980 T AT 01907980T AT 01907980 T AT01907980 T AT 01907980T AT E266021 T1 ATE266021 T1 AT E266021T1
Authority
AT
Austria
Prior art keywords
sub
sup
alkyl
hydrogen
optionally substituted
Prior art date
Application number
AT01907980T
Other languages
English (en)
Inventor
Alessandra Gaiba
Andrew Kenneth Takle
David Matthew Wilson
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE266021T1 publication Critical patent/ATE266021T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01907980T 2000-03-06 2001-03-02 Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren ATE266021T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0005357.9A GB0005357D0 (en) 2000-03-06 2000-03-06 Compounds
PCT/GB2001/000916 WO2001066540A1 (en) 2000-03-06 2001-03-02 Imidazol-2-carboxamide derivatives as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE266021T1 true ATE266021T1 (de) 2004-05-15

Family

ID=9887051

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907980T ATE266021T1 (de) 2000-03-06 2001-03-02 Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren

Country Status (12)

Country Link
US (1) US6987119B2 (de)
EP (1) EP1261602B1 (de)
JP (1) JP2003525937A (de)
AT (1) ATE266021T1 (de)
AU (1) AU2001235844A1 (de)
DE (1) DE60103133T2 (de)
DK (1) DK1261602T3 (de)
ES (1) ES2217118T3 (de)
GB (1) GB0005357D0 (de)
PT (1) PT1261602E (de)
TR (1) TR200401903T4 (de)
WO (1) WO2001066540A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1158985B1 (de) 1999-01-13 2011-12-28 Bayer HealthCare LLC GAMMA CARBOXYARYLSUBSTITUIERTE DIPHENYLHARNSTOFFVERBINDUNGEN ALS p38 KINASEHEMMER
AU1529901A (en) * 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
ATE266022T1 (de) * 2000-03-06 2004-05-15 Smithkline Beecham Plc Imidazol derivate als raf kinase inhibitoren
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121494D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US20040192689A1 (en) * 2001-09-05 2004-09-30 Dean David Kenneth Heterocycle-carboxamide derivatives as raf kinase inhibitors
WO2003022832A1 (en) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans and pyrroles as raf kinase inhibitors
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
WO2004019873A2 (en) 2002-08-29 2004-03-11 Scios Inc. Methods of promoting osteogenesis
EP1636585B2 (de) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-harnstoffe mit kinasehemmender wirkung
EP1663978B1 (de) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
WO2005030091A2 (en) 2003-09-25 2005-04-07 Scios Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US20050282909A1 (en) * 2003-11-14 2005-12-22 Diks Sander H Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
CA2577275A1 (en) * 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
MX2007002433A (es) * 2004-09-01 2007-05-04 Astrazeneca Ab Derivados de quinazolinona y su uso como inhibidores de b-raf.
EP1676574A3 (de) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Verfahren zur Förderung des Überlebens von Zell- und Gewebe-Transplantaten
AU2006304897B2 (en) * 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
WO2007124319A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
WO2009012283A1 (en) 2007-07-17 2009-01-22 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2181987B9 (de) 2007-08-23 2014-09-03 Takeda Pharmaceutical Company Limited 2-Carbonylaminobenzothiazole und ihre Verwendung zur Vorbeugung und Behandlung von Krebs
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
WO2009115572A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP3969449B1 (de) 2019-05-13 2025-02-12 Novartis AG Neue kristalline formen von n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluormethyl)isonicotinamid als raf-inhibitoren zur behandlung von krebs
WO2026041859A1 (en) * 2024-08-19 2026-02-26 Oxford University Innovation Limited Pak1 and/or pak2 activators and their use in the prevention and/or treatment of diseases or conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR75287B (de) 1980-07-25 1984-07-13 Ciba Geigy Ag
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
EP0833664A1 (de) 1995-06-12 1998-04-08 G.D. SEARLE & CO. Kombination aus einem cyclooxygenase-2 inhibitor und einem leukotrien b4 rezeptorantagonisten zur behandlung von entzündungen
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
KR19990064117A (ko) 1995-10-06 1999-07-26 폴락 돈나 엘. 항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
CA2250232A1 (en) 1996-04-03 1997-10-09 Allen I. Oliff A method of treating cancer
ES2239357T3 (es) 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
DE69729946T2 (de) 1996-10-15 2005-01-20 G.D. Searle Llc Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
AU8757098A (en) 1997-06-30 1999-02-10 Ortho-Mcneil Pharmaceutical, Inc. 2-substituted imidazoles useful in the treatment of inflammatory diseases
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
CN1213022C (zh) * 1997-12-22 2005-08-03 拜尔有限公司 用对称和不对称的取代二苯脲抑制raf激酶
JP2002516322A (ja) 1998-05-22 2002-06-04 スミスクライン・ビーチャム・コーポレイション 新規２−アルキル置換イミダゾール化合物
AU1529901A (en) 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
ATE365730T1 (de) 2000-11-20 2007-07-15 Smithkline Beecham Corp Neuartige verbindungen

Also Published As

Publication number Publication date
DE60103133D1 (de) 2004-06-09
US6987119B2 (en) 2006-01-17
EP1261602A1 (de) 2002-12-04
AU2001235844A1 (en) 2001-09-17
GB0005357D0 (en) 2000-04-26
PT1261602E (pt) 2004-08-31
TR200401903T4 (tr) 2004-09-21
ES2217118T3 (es) 2004-11-01
WO2001066540A1 (en) 2001-09-13
DK1261602T3 (da) 2004-08-30
DE60103133T2 (de) 2004-10-14
US20030134837A1 (en) 2003-07-17
JP2003525937A (ja) 2003-09-02
EP1261602B1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
DE60103133D1 (de) Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren
DE60103136D1 (de) Imidazol derivate als raf kinase inhibitoren
EP1724262A4 (de) 1-(2h)-isochinolonderivat
EA201170196A1 (ru) Производные бензазепинов и их применение в качестве h3 гистаминовых антагонистов
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EE200200148A (et) Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
RU2007110629A (ru) Ингибиторы днк-пк
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
TNSN03110A1 (en) Azaindoles.
NO20023218D0 (no) 2-amino-nikotinamidderivater og deres anvendelse som VEGF- reseptor tyrosinkinaseinhibitorer
HRP20040429B1 (hr) Derivati sulfonamida, njihova priprema i upotrebakao lijekova
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
AR047817A1 (es) Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica
NO20082077L (no) Spirosykliske quinazolinderivater som PDE7-inhibitorer
EA200601076A1 (ru) Применение производных n-арилгидразина для борьбы с вредителями
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
DE60228098D1 (de) Pyridin-substituierte furanderivate als raf-kinase inhibitoren
EA200701780A1 (ru) Противоопухолевое средство
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
DK1572198T3 (da) Farmaceutiske forbindelser med alfa2-receptoraktivitet
DK1899331T3 (da) Homomorpholinoxazolidnoner som antibakterielle midler
ATE409698T1 (de) 1,2,4-triazolderivat, verfahren zu dessen herstellung, und dieses enthaltende pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1261602

Country of ref document: EP

REN Ceased due to non-payment of the annual fee